I've read that some believe that Phase 1 Trials are the

New Post Public Reply Private Reply Replies (1) Message Board
GaryM
711
I've read that some believe that Phase 1 Trials are the easiest to run. I beg to differ. In the case of the cream, all in the trial were healthy patients, they had nothing whatsoever to gain at least healthwise from the trial. They were subjected to putting the cream on routinely, taking blood tests multiple times a week. I don't know what they may have paid the healthy patients, but clearly they had some drop outs who didn't think it was worth it.

Now we don't know how the other Phase 1's are being run, but if they have patients who have disease, they may be able to see some benefits. The problem with Phase 1 is that the dosage always starts low and escalates. In general the patients in the first few cohorts see no benefits, but as dosage increases, hopefully the benefits do as well until some sort of maximum benefit is achieved and the maximum tolerated dose is determined. In some cases, if the patients with the lower doses are still eligible, they may receive the higher dose. I'm speaking generally about cancer trials where people are dying, but somewhat the same is true here. When the dose that's determined to be most effective is determined, that's the dose that normally goes to Phase 2 or the Phase 2 portion of a Phase 1/2.

I frankly believe that Phase 2 Trials are easier to run than Phase 1 as there all the patients have the disease and can benefit from whatever is being tested. They are still relatively small trials, not that expensive to run, and they don't have the delays inherent in the safety trial where one cohort cannot begin until the prior cohort is judged to be safe after a specified period of time. Phase 2's can be blinded and run with control groups, or they can all be on the experimental drug, the trial design is up to those running the trial, as well the IRB and perhaps the FDA or similar authority. If the drug used in the trial is of Pivotal quality, it's actually possible to gain approval from such a trial if efficacy is so clear that even a blind man would see it.

To my knowledge, when OWCP says their drugs are "Market Ready" they're saying they're already commercial quality, essentially mass produced pivotal quality material. I believe that everything they're using in trials could be used to build a case for approval, the key is the results must be good enough.

No one should get too excited about what I'm saying as these trials are purely being done under Israeli authority. I have no idea if an approval there will acknowledged by anyone outside of Israel, especially if no other countries are involved in the trials.

Gary

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 323

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 247

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 312

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 522

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 371

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 44

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 238

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 495

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 265

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Valneva Faces Setback as Ixchiq Vaccine License Suspended

Updated Category News Views 213

Valneva SE's Ixchiq Vaccine Under Scrutiny Valneva SE stock (VALN) experienced a decline recently after the U.S. Food and Drug Administration (FDA) announced the suspension of its license for the Ixchiq vaccine. This decision stems from reports of serious adverse events (SAEs) linked to chikungunya-like illness, leading to concerns about the vaccine's safety profile....

Continue Reading
Tetra Tech Secures Major Water Management Deal Worth £800 Million

Updated Category News Views 114

Tetra Tech Selected for £800 Million Water Management Framework In a significant development, Tetra Tech, Inc. (NASDAQ: TTEK), a prominent provider of advanced consulting and engineering services, has been awarded a major contract by Northern Ireland Water. This framework agreement, valued at up to £800 million, aims to bolster the sustainable delivery of essential...

Continue Reading
Synedgen Secures $2.2 Million JWMRP Grant for MIIST305

Updated Category News Views 119

Synedgen Achieves Major Milestone with JWMRP Funding Synedgen, Inc., a prominent biotechnology firm, is making headlines with its recent announcement about receiving a substantial $2.2 million contract from the Joint Warfighter Medical Research Program (JWMRP). This funding is designated for the advancement of MIIST305, a pioneering therapeutic aimed at shielding...

Continue Reading
Ensurge Micropower ASA Expands Private Placement Opportunities

Updated Category News Views 210

Ensurge Micropower ASA Extends Private Placement Bookbuilding Ensurge Micropower ASA has recently made waves in the investment community with an update on its ongoing private placement. The company is taking strategic steps to extend the bookbuilding period, offering investors increased opportunities to participate. The update was shared following a stock exchange...

Continue Reading
Dale Hageman Takes Leadership Role as ESAC Board Chairman

Updated Category News Views 130

Dale Hageman to Lead ESAC Board as Chairman Spirit HR is proud to share that its CEO and Founder, Dale Hageman, has been elected Chairman of the Board for the Employer Services Assurance Corporation (ESAC). This leadership role reflects Dale’s long-standing dedication to the HR field and his steady commitment to the highest levels of financial assurance and...

Continue Reading